Image via WikipediaSeveral studies exploring the use of lapatinib (Tykerb, GlaxoSmithKline) in metastatic breast cancer have suggested that it may offer an alternative to chemotherapy in this setting, both as monotherapy, and in combination with other targeted therapies. One study explored the use of lapatinib alone, whereas others investigated combinations with trastuzumab (Herceptin, Genentech/Roche), with [...]
Entries Tagged as 'breast cancer'
Are Her2 inhibitors an alternative to chemo in breast cancer?
June 11th, 2008 · 1 Comment · breast cancer, cancer, competitive intelligence, market intelligence, market trends, oncology, pipeline
Tags:
Does aspirin lower the risk of breast cancer?
May 3rd, 2008 · No Comments · breast cancer, market intelligence, market trends, oncology, research
A daily aspirin may give women modest protection against the most common type of breast cancer according to a study published in Breast Cancer Research. The finding reinforced earlier research indicating regular use of aspirin might reduce the risk of so-called estrogen receptor-positive breast cancer, which makes up about three quarters of breast cancer cases. [...]
Tags:
Breast cancer update: will genotyping help select best patients?
April 30th, 2008 · No Comments · breast cancer, competitive intelligence, market intelligence, market trends, oncology
Previously, pharmacogenetic studies have demonstrated that women with a certain genotype have a better response to tamoxifen. Now, a modeling study has shown that for postmenopausal breast cancer patients with this genotype, tamoxifen is as good or better at reducing the risk for relapse as aromatase inhibitors. This finding does have clinical implications, but routine [...]
Tags: